Objective: Administration of infliximab is associated with a well-recognised risk of infusion
reactions. Lack of a mechanism-based rationale for their prevention, and absence of …

Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …

Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a
growing incidence and prevalence in several countries, including Italy. Although the etiology …

Treatment of ankylosing spondylitis Page 1 Turkish Journal of Medical Sciences Volume 45
Number 2 Article 25 1-1-2015 Treatment of ankylosing spondylitis İSMAİL SARI MEHMET …

Background Medication costs in inflammatory bowel disease (IBD) are now the principal
driver of health care costs. Cost-effective strategies to optimize and rationalize treatment are …

Factors influencing acute infusion reactions in inflammatory... : European Journal of
Gastroenterology & Hepatology Factors influencing acute infusion reactions in inflammatory …

Introduction In children, ulcerative colitis (UC) is often more severe and extensive than in
adults and hospitalization for acute exacerbations occurs in around a quarter of subjects …

Background Standard Infliximab infusion consists of a 2-hour intravenous administration.
Recently, Infliximab shortened infusion has been included in the Infliximab label as possible …

Objectives No gold standard exists to assess methodological quality of systematic reviews
(SRs). Although Assessing the Methodological Quality of Systematic Reviews (AMSTAR) is …

Abstract Background and Aim In patients with inflammatory bowel disease (IBD) tolerating 2-
h infusions of 5 mg/kg infliximab scheduled maintenance therapy, the infusion time can be …